Updated Jul. 17, 2013 at 5:49 a.m.

Premium Lock As blood pressure generic fails to materialize, Novartis ups full-year guidance

Published: 2013-07-17 05:40:00
Updated: 2013-07-17 05:49:13

Novartis Novartis

Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 Bloomberg. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders